Todos Med Ltd (TOMDF)

[theswordman]

Motley Fool article on long covid--interesting as it AGREES with most here about long covid therapies and treatments. A quote--Many people who suffer from long COVID can't maintain stable employment due to the symptoms, and right now, there are no therapies or cures that are known to be effective at treating its root causes, which are still under scientific investigation.

So once AGAIN--in spite of ALL the great long covid clinic stories--the symptoms just go away stories--covid is over stories--all you do is go visit 9 Drs theory. We are still with no definitive testing--no FDA approved treatments.
Viral persistence is REAL. Viral eradication is 100% require for ANY, ANY treatment to be effective (or you will end up seeing 9 Drs/ and/or a wheelchair, and/or a O2 machine, and/or a mortician)
The illness has so many symptoms -- and so many plausible potential causes for them--yeppers--what we discussed months ago; endothelial damage--micro clots/clots--gut bacteria--reactivation of ANY old viral remnants in blood

That's the first reason why the market for long COVID medicines could eventually be gargantuan. And will any of these drugs be fully effective--even work at all if there is viral persistence??--N O

https://www.fool.com/investing/2023/07/14/this-emerging-market-could-be-the-next-big-thing-i/

Will Tollovid be a part of any or all solutions??--no 1 knows. But as of now--we know that 3 CL Protease Inhibitors are the ONLY thing that work to eradicate the virus. The ONLY thing that Drs use that works on viral persisitence. Drs wanting to use something else OTHER THAN Tollovid. Drs wanting to use Paxlovid--but they use Tollovid to treat viral persistence. WHY?? Because it is snake oil--ticture--sold by Queens mafia or in some movie??--no because it works and Drs are trying to save lives. moo moo moo

Sorry I have no pix of movie stars or the CEO to attach. Just the Motley link. Cannot speak to T/A analysis or charts on a penny stock. There are some here that do accept that approach.